Contrasting BAVARIAN NORDIC/S (BVNRY) & Editas Medicine (EDIT)

BAVARIAN NORDIC/S (OTCMKTS:BVNRY) and Editas Medicine (NASDAQ:EDIT) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, earnings, profitability, dividends, analyst recommendations, risk and institutional ownership.


This table compares BAVARIAN NORDIC/S and Editas Medicine’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
BAVARIAN NORDIC/S -18.41% -6.60% -5.23%
Editas Medicine -623.35% -61.27% -35.09%

Institutional and Insider Ownership

67.2% of Editas Medicine shares are owned by institutional investors. 5.2% of Editas Medicine shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Volatility & Risk

BAVARIAN NORDIC/S has a beta of 0.68, suggesting that its share price is 32% less volatile than the S&P 500. Comparatively, Editas Medicine has a beta of 3.37, suggesting that its share price is 237% more volatile than the S&P 500.

Earnings and Valuation

This table compares BAVARIAN NORDIC/S and Editas Medicine’s revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
BAVARIAN NORDIC/S $208.06 million 3.86 $27.54 million $0.29 28.59
Editas Medicine $13.73 million 95.46 -$120.32 million ($2.98) -9.22

BAVARIAN NORDIC/S has higher revenue and earnings than Editas Medicine. Editas Medicine is trading at a lower price-to-earnings ratio than BAVARIAN NORDIC/S, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of recent ratings and recommmendations for BAVARIAN NORDIC/S and Editas Medicine, as provided by

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Editas Medicine 1 4 6 0 2.45

Editas Medicine has a consensus price target of $47.43, indicating a potential upside of 72.53%. Given Editas Medicine’s higher probable upside, analysts plainly believe Editas Medicine is more favorable than BAVARIAN NORDIC/S.


BAVARIAN NORDIC/S beats Editas Medicine on 7 of the 13 factors compared between the two stocks.


Bavarian Nordic A/S, a biotechnology company, develops, manufactures, and commercializes a portfolio of novel vaccines for the prevention and treatment of life-threatening infectious diseases and cancer. The company markets non-replicating smallpox vaccine under the IMVAMUN and IMVANE names. It is also developing MVA-BN Filo that is in Phase III trial for the treatment of Ebola and Marburg; MVA-BN RSV, which is in Phase II clinical development stage for the prevention of respiratory syncytial virus; and MVA-BN HPV that is in preclinical development stage to treat human papillomavirus. In addition, the company is developing PROSTVAC, which is in Phase III clinical development for the treatment of asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer; CV301 that is in Phase II clinical trial for the treatment multiple cancers; and MVA-BN Brachyury that has completed Phase I clinical trial for the treatment of metastatic cancer. The company has collaboration agreements with National Cancer Institute; Bristol-Myers Squibb; Janssen Pharmaceuticals, Inc.; Biomedical Advanced Research and Development Authority; US Department of Defense; and PCI Biotech. The company operates in the United States, Holland, Canada, and internationally. Bavarian Nordic A/S was founded in 1994 and is headquartered in Kvistgård, Denmark.

About Editas Medicine

Editas Medicine, Inc. operates as a genome editing company. It focuses on treating patients with genetically defined diseases by correcting their disease causing genes. The company develops a proprietary genome editing platform based on CRISPR technology to target genetically defined diseases with an initial focus on debilitating illnesses where there are no approved treatments. It develops EDIT-101 for Leber Congenital Amaurosis type 10, a genetic form of vision loss that leads to blindness in childhood. The company also develops other therapies for eye diseases, such as Herpes Simplex Virus 1 that causes lifelong infections primarily leading to ocular and oral disease; and Usher Syndrome 2A, which is a form of retinitis pigmentosa that also includes hearing loss. In addition, it develops hematopoietic stem cells for treating sickle cell disease and beta thalassemia. Editas Medicine, Inc. has a collaboration and license agreement with Juno Therapeutics, Inc. for the research and development of engineered T cells with chimeric antigen receptors and T cell receptors; and strategic alliance and option agreement with Allergan Pharmaceuticals International Limited for the research and development of medicines for ocular diseases. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine Inc. in November 2013. Editas Medicine, Inc. was founded in 2013 and is based in Cambridge, Massachusetts.

Receive News & Ratings for BAVARIAN NORDIC/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BAVARIAN NORDIC/S and related companies with's FREE daily email newsletter.

Leave a Reply